Low dose insulin like growth factor binding proteins 1 and 2 and angiopoietin like protein 3 coordinately stimulate ex vivo expansion of human umbilical cord blood hematopoietic stem cells as assayed in NOD/SCID gamma null mice

Fan, Xiubo; Gay, Florence PH; Lim, Francesca WI; Ang, Justina ML; Chu, Pat PY; Bari, Sudipto; Hwang, William YK
June 2014
Stem Cell Research & Therapy;2014, Vol. 5 Issue 3, p1
Academic Journal
Introduction Insulin like growth factors (IGFs), IGF binding proteins (IGFBPs) and angiopoietin like proteins (ANGPTLs) can enhance the ex vivo expansion of hematopoietic stem cells (HSCs) when used with a standard cytokine cocktail of stem cell factor (SCF), thrombopoietin (TPO) and FLT3-ligand (FL). In order to determine the optimal dose and combination of IGFs, IGFBPs and ANGPTLs, serial dilution and full permutation of IGFBP1, IGFBP2, IGF2 and ANGPTL3 were applied on cryopreserved umbilical cord blood (UCB) mononuclear cells (MNCs) ex vivo expansion system. Methods In this system, 4 × 105 cells/mL of UCB-MNCs were inoculated in serum-free Stemspan® medium supplied with standard basal cytokine combination of 100 ng/ml SCF, 50 ng/ml FL and 100 ng/ml TPO and supported by a bone marrow (BM) mesenchymal stromal cells (MSCs) stromal layer. Results Paradoxically, experiment results showed that the highest expansion of CD34+CD38-CD90+ primitive progenitor was stimulated by cytokine combination of "SCF + TPO + FL + IGFBP1 + IGFBP2 + ANGPTL3" at a low dose of 15 ng/ml IGFBP1 and 20 ng/ml of IGFBP2 and ANGPTL3. This ex vivo expansion was further validated in 8-10 weeks nonobese diabetic/severe combined immunodeficiency interleukin 2 gamma chain null (NOD/SCID-IL2Rβ-/-) mice. Limiting dilution assay showed excellent correlation between the hematopoietic stem cells (HSCs) ex vivo surface marker of CD34+CD38-CD90+ and the in vivo competitive repopulating unit (CRU) functional assay. Conclusion IGFBP1, IGFBP2, IGF2 and ANGPTL3 can stimulate the expansion of CD34+CD38-CD90+ primitive progenitor at low dose. The optimal combination comprises IGFBP1, IGFBP2 and ANGPTL3 together with the standard cytokine cocktail of SCF, FL and TPO. The CD34+CD38-CD90+ phenotype can serve as a surrogate ex vivo surface marker for HSCs due to consistency with in vivo CRU functional assay.


Related Articles

  • Angiopoietin-Like Protein 3 Promotes Preservation of Stemness during Ex Vivo Expansion of Murine Hematopoietic Stem Cells. Farahbakhshian, Elnaz; Verstegen, Monique M.; Visser, Trudi P.; Kheradmandkia, Sima; Geerts, Dirk; Arshad, Shazia; Riaz, Noveen; Grosveld, Frank; van Til, Niek P.; Meijerink, Jules P. P. // PLoS ONE;Aug2014, Vol. 9 Issue 8, p1 

    Allogeneic hematopoietic stem cell (HSC) transplantations from umbilical cord blood or autologous HSCs for gene therapy purposes are hampered by limited number of stem cells. To test the ability to expand HSCs in vitro prior to transplantation, two growth factor cocktails containing stem cell...

  • The Thrombopoietin Receptor Agonist Eltrombopag Inhibits Human Cytomegalovirus Replication Via Iron Chelation. Vogel, Jens-Uwe; Schmidt, Sophie; Schmidt, Daniel; Rothweiler, Florian; Koch, Benjamin; Baer, Patrick; Rabenau, Holger; Michel, Detlef; Stamminger, Thomas; Michaelis, Martin; Cinatl, Jindrich // Cells (2073-4409);Jan2020, Vol. 9 Issue 1, p1 

    The thrombopoietin receptor agonist eltrombopag was successfully used against human cytomegalovirus (HCMV)-associated thrombocytopenia refractory to immunomodulatory and antiviral drugs. These effects were ascribed to the effects of eltrombopag on megakaryocytes. Here, we tested whether...

  • Ex Vivo Expansion of Human Hematopoietic Stem Cells by Garcinol, a Potent Inhibitor of Histone Acetyltransferase. Nishino, Taito; Wang, Changshan; Mochizuki-Kashio, Makiko; Osawa, Mitsujiro; Nakauchi, Hiromitsu; Iwama, Atsushi // PLoS ONE;2011, Vol. 6 Issue 9, p1 

    Background: Human cord blood (hCB) is the main source of hematopoietic stem and progenitor cells (HSCs/PCs) for transplantation. Efforts to overcome relative shortages of HSCs/PCs have led to technologies to expand HSCs/PCs ex vivo. However, methods suitable for clinical practice have yet to be...

  • A strategy for enhancing the engraftment of human hematopoietic stem cells in NOD/SCID mice. Lee, Soo Hyun; Kim, Dae Seong; Lee, Myoung Woo; Noh, Yoo Hun; Jang, In Keun; Kim, Dong Hyun; Yang, Heung-Mo; Kim, Sung-Joo; Choi, Soo Jin; Oh, Wonil; Yang, Yoon Sun; Chueh, Hee Won; Son, Meong Hi; Jung, Hye Lim; Yoo, Keon Hee; Sung, Ki Woong; Koo, Hong Hoe // Annals of Hematology;Dec2013, Vol. 92 Issue 12, p1595 

    To overcome the limitations of allogeneic hematopoietic stem cell transplantation (HSCT), we conducted a study to identify a strategy for enhancing hematopoietic stem cell (HSC) engraftment during HSCT. Co-transplantation experiments with mesenchymal stem cells (MSCs) derived from adult human...

  • Mesenchymal Stromal Cells: The Magic Band-Aid? Kebriaei, Partow // Acta Haematologica;Nov2014, Vol. 133 Issue 1, p70 

    No abstract available

  • Physicians Poster AbstractsEBMT 2011.  // Bone Marrow Transplantation;Apr2011 Supplement, Vol. 46, pS90 

    The article presents abstracts on medical topics which include "Personalized modelling-based gene selection for developing an early acute GvHD diagnosis support system," by M. Cuzzola and colleagues, "TCR-like positive neutrophil reconstitution following haematopoietic stem cell...

  • Repairing Damaged Goods: Mesenchymal Stromal Cell Therapy for Secondary Failure of Hematopoiesis Post-Allogeneic Hematopoietic Cell Transplant. Holtan, Shernan G.; Newell, Laura F.; Chandran, Rekha; Markovic, Svetomir N.; Porrata, Luis F. // Journal of Stem Cell Research & Therapy;2012, Vol. 2 Issue 5, Special section p1 

    The authors examine the efficacy of mesenchymal stromal cell therapy for secondary failure of hematopoiesis post-allogeneic hematopoietic cell transplant (HCT). They explore the potential of HCT to cure high-risk or advanced cancers of the blood such as acute leukemia. They suggest, however, the...

  • Infections caused by Mycobacterium tuberculosis in recipients of hematopoietic stem cell transplantation. Kebriaei, Partow; Hamdi, Amir // Frontiers in Oncology;Aug2014, Vol. 4, p1 

    Mycobacterium tuberculosis (M. tuberculosis) infections are uncommon in recipients of hematopoietic stem cell transplantation. These infections are 10-40 times commoner in recipients of stem cell transplantation than in the general population but they are 10 times less in stem cell...

  • Rhinosinusitis in Hematopoietic Stem Cell-Transplanted patients: influence of nasosinus mucosal abnormalities? Ortiz, Erica; Altemani, Albina; Vigorito, Afonso Celso; Sakano, Eulalia; Danielli Nicola, Ester Maria // Stem Cell Research & Therapy;2014, Vol. 5 Issue 6, p28 

    Introduction Rhinosinusitis (RS) is characterized by inflammation extending from the mucosa of the nasal cavity into the paranasal sinuses. There are some aggravating features, such as immunosuppression, that can cause the nasal mucosal inflammation to linger for a long period, resulting in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics